Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOR-582 for Epistaxis in Hereditary Hemorrhagic Telangiectasia
NCT07667413Phase 1Not yet recruiting
- Sponsor
- Columbia University
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirolimus in hereditary hemorrhagic telangiectasia (HHT) and epistaxis (3 arms), sponsored by Columbia University. Primary endpoints: Incidence of dose-limiting toxicities at 4 weeks, Number of participants with treatment-emergent adverse events at 12 weeks and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on NCT07667413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667413.